Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<p>In our April International Strategy, we explore the recent consolidation across global equity markets and examine the following opportunities within:</p><ul><li>Defensive Sectors, including an actionable Group within Health Care: Pharmaceuticals</li><li>Japan and Hong Kong</li><li>Emerging Markets</li></ul><p>Also included are links to in-depth commentary on all 12 sectors</p>

In our April International Strategy, we explore the recent consolidation across global equity markets and examine the following opportunities within:Defensive Sectors, including an actionable Group within Health Care: PharmaceuticalsJapan and Hong KongEmerging MarketsAlso included are links to in-depth commentary on all 12 sectors

Global Equity Strategy: Opportunities in Japan, HK, &  EM

Taiwan

TSH Biopharm Corporation Ltd.develops, manufactures and markets drugs for cadiovascular, gastrointestinal and central nervous system diseases.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Tsh Biopharm Corp (8432 TT)

Global Equity Strategy: Opportunities in Japan, HK, & EM

In our April International Strategy, we explore the recent consolidation across global equity markets and examine the following opportunities...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)